Carol Kruchko Ba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1058738/publications.pdf

Version: 2024-02-01

43 papers

11,095 citations

218677 26 h-index 265206 42 g-index

43 all docs 43 docs citations

times ranked

43

13449 citing authors

#	Article	IF	CITATIONS
1	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro-Oncology, 2019, 21, v1-v100.	1.2	1,735
2	CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-Oncology, 2015, 17, iv1-iv62.	1.2	1,727
3	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro-Oncology, 2018, 20, iv1-iv86.	1.2	1,624
4	CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-Oncology, 2017, 19, v1-v88.	1.2	1,236
5	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology, 2020, 22, iv1-iv96.	1.2	1,175
6	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro-Oncology, 2021, 23, iii1-iii105.	1.2	804
7	Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011. Neuro-Oncology, 2015, 16, x1-x36.	1.2	414
8	Brain and other central nervous system tumor statistics, 2021. Ca-A Cancer Journal for Clinicians, 2021, 71, 381-406.	329.8	404
9	Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. JAMA Oncology, 2018, 4, 1254.	7.1	373
10	Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro-Oncology, 2015, 17, 1166-1173.	1.2	169
10		1.2	169 159
	the United States. Neuro-Oncology, 2015, 17, 1166-1173. The elderly left behindâ€"changes in survival trends of primary central nervous system lymphoma over		
11	the United States. Neuro-Oncology, 2015, 17, 1166-1173. The elderly left behindâ€"changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro-Oncology, 2018, 20, 687-694. Global incidence of malignant brain and other central nervous system tumors by histology,	1.2	159
11 12	the United States. Neuro-Oncology, 2015, 17, 1166-1173. The elderly left behindâ€"changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro-Oncology, 2018, 20, 687-694. Global incidence of malignant brain and other central nervous system tumors by histology, 2003â€"2007. Neuro-Oncology, 2017, 19, 1553-1564. Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries.	1.2	159 146
11 12 13	the United States. Neuro-Oncology, 2015, 17, 1166-1173. The elderly left behindâ€"changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro-Oncology, 2018, 20, 687-694. Global incidence of malignant brain and other central nervous system tumors by histology, 2003â€"2007. Neuro-Oncology, 2017, 19, 1553-1564. Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries. Neuro-Oncology, 2012, 14, 1194-1200. The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010.	1.2 1.2 1.2	159 146 129
11 12 13	the United States. Neuro-Oncology, 2015, 17, 1166-1173. The elderly left behindâ€"changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro-Oncology, 2018, 20, 687-694. Global incidence of malignant brain and other central nervous system tumors by histology, 2003â€"2007. Neuro-Oncology, 2017, 19, 1553-1564. Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries. Neuro-Oncology, 2012, 14, 1194-1200. The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. Neuro-Oncology, 2014, 16, 1392-1399. Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United	1.2 1.2 1.2	159 146 129 100
11 12 13 14	the United States. Neuro-Oncology, 2015, 17, 1166-1173. The elderly left behindâ€"changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro-Oncology, 2018, 20, 687-694. Global incidence of malignant brain and other central nervous system tumors by histology, 2003â€"2007. Neuro-Oncology, 2017, 19, 1553-1564. Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries. Neuro-Oncology, 2012, 14, 1194-1200. The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. Neuro-Oncology, 2014, 16, 1392-1399. Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro-Oncology, 2016, 18, 70-77. Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis. Cancer Epidemiology	1.2 1.2 1.2 1.2	159 146 129 100

#	Article	IF	Citations
19	Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. Journal of Neuro-Oncology, 2017, 135, 433-441.	2.9	62
20	Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005–2015, using the Central Brain Tumor Registry of the United States. Neuro-Oncology, 2019, 21, 380-391.	1.2	59
21	Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro-Oncology, 2017, 19, now252.	1,2	48
22	The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro-Oncology, 2018, 20, 295-298.	1.2	46
23	Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry. Frontiers in Public Health, 2016, 4, 151.	2.7	40
24	Consensus Conference on Brain Tumor Definition for Registration. Neuro-Oncology, 2002, 4, 134-145.	1.2	40
25	Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. Neuro-Oncology Practice, 2022, 9, 165-182.	1.6	40
26	Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. Neuro-Oncology Practice, 2019, 6, 451-462.	1.6	36
27	Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. Neuro-Oncology, 2022, 24, 302-310.	1.2	29
28	Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017. Neuro-Oncology, 2021, 23, 990-998.	1.2	28
29	Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro-Oncology, 2022, 24, 1989-2000.	1.2	27
30	A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. Neuro-Oncology, 2022, 24, 1341-1349.	1.2	20
31	Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. Journal of Neuro-Oncology, 2017, 133, 17-25.	2.9	17
32	Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors. Neuro-Oncology Practice, 2019, 6, 330-339.	1.6	17
33	Brain tumors and COVID-19: the patient and caregiver experience*. Neuro-Oncology Advances, 2020, 2, vdaa104.	0.7	17
34	An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program. Neuro-Oncology Advances, 2021, 3, vdaa175.	0.7	14
35	Pilocytic astrocytoma: Where do they belong in cancer reporting?. Neuro-Oncology, 2019, 22, 298-300.	1.2	11
36	Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database. Neuro-Oncology Advances, 2021, 3, vdab040.	0.7	7

#	Article	IF	CITATIONS
37	Racial/ethnic differences in survival for patients with gliosarcoma: an analysis of the National cancer database. Journal of Neuro-Oncology, 2019, 143, 349-357.	2.9	6
38	The brain tumor not-for-profit and charity experience of COVID-19: reacting and adjusting to an unprecedented global pandemic in the 21st century. Neuro-Oncology Advances, 2021, 3, vdaa166.	0.7	6
39	Epidemiology of Pineoblastoma in the United States, 2000-2017. Neuro-Oncology Practice, 2022, 9, 149-157.	1.6	4
40	Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States. Neuro-Oncology Practice, 2020, 7, 299-305.	1.6	3
41	Epidemiology of primary malignant non-osseous spinal tumors in the United States. Spine Journal, 2022, , .	1.3	3
42	Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions. Neuro-Oncology Practice, 2022, 9, 317-327.	1.6	3
43	Brain tumour patients and COVID-19 vaccines: results of an international survey. Neuro-Oncology Advances, 0 , , .	0.7	1